PIK3CA and breast neoplasm: Given the treatment option of PI3K inhibitors in patients with HR + /HER2- metastatic breast cancer, the temporal heterogeneity within breast tumors and the diagnostic challenges associated with identification of mutational status, reliable identification of PIK3CA-mutated patients who will benefit from treatment with PI3K inhibitors remains of outmost importance.